daw
05-25-2005, 01:21 AM
Presentation at May Digestive Disease Week 2005
Presentation Number: S1691
Disclosures: None
A Prospective Multi-Center Evaluation Of Ablation Of Non Dysplastic Barrett’s Esophagus Using the Barrx Bipolar Balloon Device. the Ablation Of Intestinal Metaplasia (aim)-Ii Trial.
Authors: D.E. Fleischer, V. Sharma, A. Reymunde, M. Kimmey, R. Chuttani, B. Overholt, K. Chang, C. Lightdale, N. Santiago, D. Pleskow, P. Dean, K. Wang
Aims: To evaluate the effectiveness, safety& tolerability of ablating non-dysplastic esophageal intestinal metaplasia (IM) using the BARRx device.
Methods: Multicenter, prospective trial in 70 patients with 2-6 cm of esophageal IM treated at 300 W; 10 J/cm2. The BARRx device has a bipolar electrode catheter encircling an esophageal balloon. In our pilot study (AIM-I) these settings resulted in circumferential ablation of IM to the muscularis mucosae while lower energy density settings resulted in insufficient ablation. All patients received esomeprazole (40 mg bid) 1 mo post-ablation, then 40 mg qd. Patient tolerability was assessed using 0-100 VAS querying peri- & 2 hr post-procedure discomfort, & a 14-day symptom diary.
All patients had EGD at 1, 3, 6 mo with 4-quadrant, q 2 cm biopsies (bx), using maximum capacity forceps; interpreted by a central/ blinded pathologist. Complete Response (CR) = all bx negative for IM; Partial Response (PR) = 50-99% bx negative for IM. Biopsy clearance rate (BCR) = % negative bx / patient at each time interval. Data reported for 1 and 3 mo represent single treatment results. If bx positive for IM at 1 or 3 mo, patients were offered a second treatment at 4 mo.
Results: Seventy patients (50 men, mean age 56.0 years, range 26-79, mean IM 3.5 cm) enrolled at 8 centers. Median procedure time = 29 min (range 3-62). RF delivery time <1 sec / 3 cm IM. All tolerated the procedure well, with low discomfort scores on exit survey & 14-day diary (median scores <20/100, complete resolution <5 day). At follow-up EGD, there was complete epithelial healing with no strictures. There were no “buried Barrett glands” in1305 follow-up bx.
At 3 mo, CR and PR rates are 41% & 54%, respectively; median BCR of 88%. Patients not in CR at 3 mo, nonetheless had the majority of their IM eliminated, with typically minute foci of IM remaining. These patients are receiving a second treatment at 4 mo. Complete follow-up at 3, 6 mo is pending.
Conclusion: The BARRx bipolar balloon device is effective in creating a circumferential ablation of IM without any significant complications, stricture formation or buried glands. Single treatment CR is 43%, while remaining patients demonstrated significant reduction in IM surface area. These results suggest that IM can be safely removed after a single treatment in a significant proportion of patients & those with residual IM can be safely retreated.
Presentation Number: S1691
Disclosures: None
A Prospective Multi-Center Evaluation Of Ablation Of Non Dysplastic Barrett’s Esophagus Using the Barrx Bipolar Balloon Device. the Ablation Of Intestinal Metaplasia (aim)-Ii Trial.
Authors: D.E. Fleischer, V. Sharma, A. Reymunde, M. Kimmey, R. Chuttani, B. Overholt, K. Chang, C. Lightdale, N. Santiago, D. Pleskow, P. Dean, K. Wang
Aims: To evaluate the effectiveness, safety& tolerability of ablating non-dysplastic esophageal intestinal metaplasia (IM) using the BARRx device.
Methods: Multicenter, prospective trial in 70 patients with 2-6 cm of esophageal IM treated at 300 W; 10 J/cm2. The BARRx device has a bipolar electrode catheter encircling an esophageal balloon. In our pilot study (AIM-I) these settings resulted in circumferential ablation of IM to the muscularis mucosae while lower energy density settings resulted in insufficient ablation. All patients received esomeprazole (40 mg bid) 1 mo post-ablation, then 40 mg qd. Patient tolerability was assessed using 0-100 VAS querying peri- & 2 hr post-procedure discomfort, & a 14-day symptom diary.
All patients had EGD at 1, 3, 6 mo with 4-quadrant, q 2 cm biopsies (bx), using maximum capacity forceps; interpreted by a central/ blinded pathologist. Complete Response (CR) = all bx negative for IM; Partial Response (PR) = 50-99% bx negative for IM. Biopsy clearance rate (BCR) = % negative bx / patient at each time interval. Data reported for 1 and 3 mo represent single treatment results. If bx positive for IM at 1 or 3 mo, patients were offered a second treatment at 4 mo.
Results: Seventy patients (50 men, mean age 56.0 years, range 26-79, mean IM 3.5 cm) enrolled at 8 centers. Median procedure time = 29 min (range 3-62). RF delivery time <1 sec / 3 cm IM. All tolerated the procedure well, with low discomfort scores on exit survey & 14-day diary (median scores <20/100, complete resolution <5 day). At follow-up EGD, there was complete epithelial healing with no strictures. There were no “buried Barrett glands” in1305 follow-up bx.
At 3 mo, CR and PR rates are 41% & 54%, respectively; median BCR of 88%. Patients not in CR at 3 mo, nonetheless had the majority of their IM eliminated, with typically minute foci of IM remaining. These patients are receiving a second treatment at 4 mo. Complete follow-up at 3, 6 mo is pending.
Conclusion: The BARRx bipolar balloon device is effective in creating a circumferential ablation of IM without any significant complications, stricture formation or buried glands. Single treatment CR is 43%, while remaining patients demonstrated significant reduction in IM surface area. These results suggest that IM can be safely removed after a single treatment in a significant proportion of patients & those with residual IM can be safely retreated.